Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE): a non-randomized phase 2 trial
Patients diagnosed with metastatic castration-refractory prostate cancer (mCRPC) rely on a limited number of therapeutic agents resulting in a median survival of 2 –3 years. A subgroup of those patients with mC...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Charlien Berghen, Steven Joniau, Kato Rans, Ga ëtan Devos, Kenneth Poels, Koen Slabbaert, Herlinde Dumez, Maarten Albersen, Karolien Goffin, Karin Haustermans and Gert De Meerleer Tags: Study protocol Source Type: research